A Study of the Safety and Efficacy of A-60444 in Adults With Respiratory Syncytial Virus (RSV) Infection Following HSCT

Inclusion Criteria: Patients diagnosed with RSV infection who have had a stem cell transplant. Female patients must be of non-childbearing potential or have a negative pregnancy test prior to study start and be deemed not at risk of becoming pregnant. Females of non-childbearing potential are defined as women who have had a hysterectomy, bilateral oophorectomy, tubal ligation, or who have been post-menopausal for at least two years; or are considered to be sterile due to recent chemotherapy. Aged between 18 and 65 years. Patients who have given their written informed consent to participate in the study. Patients who are willing and able to comply with the protocol and study procedures. Exclusion Criteria: Patients who have received an investigational drug within one month preceding the start of dosing. Patients who have a documented history of allergy to benzodiazepines. Patients with significant hepatic impairment (alanine transaminase [ALT] more than 5 x upper level of normal [ULN], total bilirubin more than 3 x ULN). Biochemistry data collected four weeks prior to screening is acceptable. Patients, who in the opinion of their general practitioner or the Investigator, should not participate in the study.